U.S. FDA Approves Pfizer's VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)Business Wire • 10/13/23
FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Pfizer's BRAFTOVI® (encorafenib) in Combination With MEKTOVI® (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLCBusiness Wire • 10/12/23
The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and PfizerZacks Investment Research • 10/12/23
FDA approves Pfizer's Braftovi plus Mektovi for a type of non-small cell lung cancerMarket Watch • 10/12/23
U.S. FDA Approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerBusiness Wire • 10/12/23
Is Pfizer Stock A Buy After The FDA Approved Its Updated Covid Shot?Investors Business Daily • 10/11/23
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?The Motley Fool • 10/11/23
Pfizer (PFE) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 10/09/23
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious DiseasesBusiness Wire • 10/05/23